Getting infected with the Zika virus results from mosquito bites. This makes Zika a
mosquito-borne disease and is transmitted via the Aedes genus. Zika is transmitted akin to
other mosquito-borne illnesses and can also be transferred from one person to another
through sexual intercourse. An infected pregnant woman may also pass the virus to her
unborn child.
Rising endeavors to contain the spread of this virus by the US FDA (United States Food and
Drug Administration) are estimated to propel the market during 2017 to 2023 (forecast
period). Moreover, initiatives taken by the US Department of Health & Human Services
check the virus from infecting more people. These initiatives have also driven the need for
Zika virus testing in the United States and other parts of the globe.
Back in August 2016, the FDA declared the testing of all donated blood products for Zika.
This was done with the intention of preventing Zika spread through blood transfusion. The
attempt paid off, with many people staying clear of the virus and keeping healthy. If this
project was not undertaken, hundreds of people could have been contaminated with the
virus.
Most of the demand for these tests are predicted to stem from Florida. The city’s burgeoning
Zika-affected population will contribute to the same. Wrong results from faulty diagnostic
procedures and shortage of awareness across emerging nations can negatively impact the
Zika Virus Testing Market.
Significant investments by the FDA and US government to introduce Zika testing in the
hospitals and banks of the United States would also drive market sales in the near future.
Moreover, attempts by vendors and producers to come up with Zika virus testing will assist
the market in gaining more traction.
Division/Classification
The global industry is split on account of tests, end-users, and regions. The tests include
serological/Zika virus antibody and molecular/nucleic acid amplification. Diagnostic units,
hospitals, pathology labs, etc. form the end-users. By regions, the Zika Virus Testing Market
is divided on the basis of Asia Pacific, Europe, Americas, and the Middle East and Africa.
Regional Overview
The constant transmission of Zika in various American nations is reported to augment the
need for testing services till 2023. Moreover, projects undertaken by the HHS, BARDA to
boost diagnostic assay innovations for the identification and treatment of this illness could
propel industry expansion over the forecast period.
Additionally, there is more outburst of the Zika virus across multiple Latin American nations.
For instance, twenty one of the twenty six states in Brazil are affected by the Zika virus.
Faster transmission in the world is projected to lead to the creation of more detection
assays, thus steering the market incomes.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5662 .
Eminent Players and Industry Advancements
Prominent companies affiliated with the Zika Virus Testing Market comprise Luminex
Corporation, ARUP Laboratories, Roche Molecular Systems, Hologic, and Siemens Healthcare
Diagnostics. To create efficient treatments and vaccines, advanced animal models are
required. An improved comprehension of immunological protection correlates is also needed
to protect ourselves from this disease.
Nowadays, the Zika virus is detected in view of clinical manifestations. Molecular detection
and serological devices also play a major role. As the separation of this virus is difficult;
LFAs, NASBA, and LAMP are used to detect the virus and ascertain the cause of the fever.
These novel techniques have assisted in accurate & fast diagnosis. With the clinical
symptoms of Zika not being pathognomic, the presence of this virus can be established only
when it is separated and examined.
Few among many clinical symptoms of this disease are myalgia, headache, fever,
maculopapular rashes, and arthralgia. Only upon further diagnosis and confirmation, are the